NDAINTRAVENOUSPOWDERPriority Review
Approved
Jul 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
KINEVAC (sincalide) by Bracco. Approved for cholecystokinin analog [epc]. First approved in 1976.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KINEVAC (sincalide) is a cholecystokinin (CCK) analog administered intravenously as a lyophilized powder, approved in 1976 for diagnostic imaging of gallbladder function. It stimulates gallbladder contraction to facilitate hepatobiliary scintigraphy and assess sphincter of Oddi dysfunction. The drug mimics natural CCK to enhance visualization of biliary and pancreatic ductal systems during imaging procedures.
LOE Approaching
As a legacy diagnostic product approaching LOE with minimal competitive pressure (30%), the brand team is likely small and focused on maintaining reimbursement and institutional relationships rather than growth.
Mechanism of Action
Pharmacologic Class:
Cholecystokinin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
Started May 2008
60 enrolled
Healthy
Career Relevance
Working on KINEVAC offers stability in a mature diagnostic franchise but limited growth trajectory or career acceleration. Roles are highly specialized in hospital relationships, imaging protocol support, and reimbursement defense rather than innovation or launch activities.
Brand Manager (Diagnostics)
Worked on KINEVAC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.